MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/hon.3112

Медицинская библиотека · Hematological oncology · 2023

15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.

Mei Chen, Ye Li, Ren Yanling, Zhou Xinping, Ma Liya, Xu Gaixiang, Xu Weilai, Lu Chenxi, Yang Haiyang, Luo Yingwan, Jiang Lingxu, Lang Wei, Zhu HongHu, Jin Jie, Tong Hongyan

СтатьяПеревод в очереди

Аннотация

The treatment of patients with refractory and/or relapsed (R/R) high-risk myelodysplastic syndrome (HR-MDS) remains a daunting clinical challenge. Venetoclax is a selective BCL-2 inhibitor, which combined with hypomethylating agents (HMAs), increased responses and prolonged survival in unfit and previously untreated acute myeloid leukemia. We performed a retrospective study of patients with R/R HR-MDS receiving combination azacytidine (AZA) plus 15-days duration of venetoclax (VEN-15d) in order to determine their efficacy and toxicity in this context. We showed that the overall response rate was 57.2% (20/35) and the median over survival was 14 months in R/R MDS. The most common treatment-emergent adverse events were peripheral blood cytopenias and infectious complications. Our retrospective study showed that the real-world experience of treating R/R MDS with AZA plus VEN-15d highlights an encouraging response rate with myelosuppression being the major toxicity. Of note, VEN-15d with AZA may salvage patients failing to respond optimally to HMAs and reduce the disease-burden for subsequent allogeneic stem cell transplantation in our analysis. These data of combination AZA plus VEN-15d in R/R MDS warrant further prospective evaluation in clinical trials.

Для цитирования: Mei Chen, Ye Li, Ren Yanling, Zhou Xinping, Ma Liya, Xu Gaixiang, Xu Weilai, Lu Chenxi, Yang Haiyang, Luo Yingwan, Jiang Lingxu, Lang Wei, Zhu HongHu, Jin Jie, Tong Hongyan. 15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.. Hematological oncology. 2023. DOI: 10.1002/hon.3112.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.